MOLECULAR ANALYSIS OF HTLV-III AND DEVELOPMENT OF DIAGNOTIC AND VACCINE REAGENTS FOR AIDS

Kapitel in diesem Buch

1. Frontmatter I
2. CONTENTS VII
3. PREFACE V
4. WHAT DOES "MARKER" MEAN? 3
5. BIOMARKERS AND COLORECTAL CANCER GENETICS: LYNCH SYNDROMES I AND II 13
6. THE HUMAN C-MXB PROTQ-ONCOGENE PRODUCT: IDENTIFICATION AND DETECTION IN IMMATURE LYMPHOID, ERYTHROID, AND MYELOID CELLS 33
7. UPDATE ON PROTO-ONCOGENES AND HUMAN CANCER 49
8. REGULATION OF THE ADENYLATE CYCLASE ACTIVITY OF CRI4 YEAST MUTANTS BY GTP AND GDP 65
9. RESTRICTION FRAGMENT LENGTH POLYMORPHISMS (RFLPs) AS GENETIC TUMOR MARKERS 71
10. dbl: A NEW TRANSFORMING GENE ISOLATED FROM A HUMAN DIFFUSE B-CELL LYMPHOMA 83
11. DEREGULATED ONCOGENES AS MARKERS FOR MELANOMA FORMATION IN XIPHOPHORUS 93
12. GENE MODULATION BY TUMOR PROMOTERS 101
13. MOLECULAR ANALYSIS OF HTLV-III AND DEVELOPMENT OF DIAGNOTIC AND VACCINE REAGENTS FOR AIDS 117
14. Transforming properties of human cytomegalovirus 129
15. GENOMIC MARKERS OF TUMORS 151
16. THE ENIGMA OF A HUMAN TUMOR MARKER: TPA REVISITED 169
17. THE ENIGMA OF A HUMAN TUMOR MARKER: TPA REVISITED 169
18. ALPHA-FETOPROTEIN: ITS DIAGNOSTIC SPECIFICITY AND THERAPEUTIC USE OF ITS ANTIBOBY 181
19. NUCLEOLAR ANTIGENS IN CANCER TISSUES 203
20. POSSIBLE RELATIONSHIP OF MOUSE MAMMARY TUMOR VIRUS (MMTV) TO HUMAN CYTOTROPHOBLAST 223
21. TUMOR ASSOCIATED ANTIGENS FOR INDICATION AND CONTROL OF THERAPY 229
22. TUMOR MARKERS IN THE PATIENT WITH LUNG CANCER 241
23. TPA AND CEA. 7 YEARS OF CLINICAL EXPERIENCE 255
24. BIOCHEMICAL MARKERS IN PANCREATIC CANCER DIAGNOSIS 267
25. FACTORS CONTRIBUTING TO SUPPRESSION OF TUMOUR-HOST RESPONSIVENESS 279
26. ALPHAFETOPROTEIN: THE EPITOME OF CANCER MARKERS 301
27. RESPONSES OF PATIENTS TO THEIR CARCINOMA-ASSOCIATED T AND Tn-SPECIFIC ANTIGENS 315
28. INTERMEDIATE FILAMENTS AND DESMOSOME-ASSOCIATED PROTEINS (DESMOPLAKINS) IN MORPHOLOGIC TUMOR DIAGNOSIS 333
29. CHROMOSOMES AS HUMAN TUMOR MARKERS 355
30. IMMUNODIAGNOSIS OF HUMAN CARCINOMAS USING MONOCLONAL ANTIBODIES 377
31. USE OF ANTI-HCG MONOCLONALS IN RIA AND IMMUNOHISTOCHEMISTRY 387
32. MONOCLONAL ANTIBODY DEFINED MARKERS OF HUMAN MELANOMA CELLS 403
33. A MOLECULAR ANALYSIS OF THE CARCINOEMBRYONIC ANTIGEN (CEA) BY MONOCLONAL ANTIBODIES 415
34. MHC STATUS OF PRIMARY HUMAN COLORECTAL CARCINOMA 421
35. ASSESSMENT OF TUMOR ASSOCIATED MONOCLONAL ANTIBODY IN IMMUNOTHERAPY IN SYNGENEIC MODEL 435
36. PSEUDOURIDINE IN BIOLOGICAL FLUIDS OF TUMOR-BEARING PATIENTS 451
37. PSEUDOURIDINE EXCRETION IN EXPERIMENTAL NEOPLASIAS OF RETROVIRAL ORIGIN 463
38. HIGH RESOLUTION QUANTITATIVE RP-HPLC-UV OF NUCLEOSIDES IN RNAs, DNAs, AND mRNAs 475
39. ANALYSIS OF RIBONUCLEOSIDES IN HUMAN BODY FLUIDS AND THEIR POSSIBLE ROLE AS PATHOBIOCHEMICAL MARKERS 503
40. NUCLEOSIDE PROFILES BY HPLC-UV IN SERUM AND URINE OF CONTROLS AND CANCER PATIENTS 519
41. ABERRANT URINARY EXCRETION OF MODIFIED NUCLEOSIDES IN PATIENTS WITH VARIOUS MANIFESTATIONS OF INFECTION WITH HTLV-III/LAV 545
42. ACTIVATION OF CELLULAR ONCOGENES FOLLOWING CHROMOSOMAL REARRANGEMENTS AS A POSSIBLE PATHOGENETIC MECHANISM IN HTLV-I POSITIVE AND NEGATIVE T-HELPER-PHENOTYPE CLL 561
43. THERAPEUTIC OPTIONS IN ACUTE LEUKEMIAS 569
44. CHARACTERIZATION OF HUMAN NON-T ACUTE LYMPHOBLASTIC LEUKAEMIA: RESULTS OF A MULTICENTRE STUDY 585
45. HUMAN INTERLEUKIN 1 (ILI) AND INTERLEUKIN 2 (IL2) CAN FUNCTION AS AUTOCRINE GROWTH FACTORS FOR SOME NEOPLASTIC HUMAN LYMPHOID CELLS 599
46. LONG TERM FOLLOW-UP AND THERAPY MONITORING OF CANCER: IS THE SIMULTANEOUS DOSAGE OF CEA AND TPA USEFUL? 613
47. NEW STRATEGIES FOR FOLLOW UP OF BREAST CANCER PATIENTS USING CEA, TPA, CA 15-3 AND CA 50 621
48. SERUM LIPID SIALIC ACID (LASA) TEST IN DETECTION AND MONITORING OF MALIGNANCIES, PARANEOPLASTIC AND RHEUMATHOID SYNDROMES 631
49. CLINICAL EVALUATION OF NEW TUMOR-ASSOCIATED ANTIGENS 643
50. AN OVERVIEW OF RESULTS. FUTURE PERSPECTIVES OF RADIOIMMUNODETECTION 657
51. TUMOR IMAGING WITH RADIOLABELLED ANTIBODIES 663
52. HORMONES IN LUNG CANCER 675
53. CLINICAL VALIDATION OF IMMUNORADIOMETRIC ASSAY FOR MEASURING SERUM THYROGLOBULIN IN ANTI-THYROGLOBULIN AUTOANTIBODY POSITIVE SERA IN PATIENTS WITH THYROID CANCER 695
54. ALTERATIONS OF MEMBRANE TSH-RECEPTOR IN THYROID TUMORS 701
55. BINDING OF THE ESTROGEN RECEPTOR TO DEFINED REGIONS OF THE ESTROGEN RESPONSIVE CHICKEN OVALBUMIN GENE AND CONSTRUCTION OF A CONSENSUS SEQUENCE FOR THE DNA SITE WHICH BINDS THE RECEPTOR 717
56. NEW DEVELOPMENTS IN TUMOR MARKERS AND RECEPTORS IN HEAD AND NECK TUfORS 731
57. REGULATION OF HORMONE BINDING OF 17β-ESTRADIOL RECEPTOR BY TYROSINE PHOSPHORYLATION AND PHOSPHOTYROSINE DEPHOSPHORYLATION OF THE RECEPTOR 755
58. SELECTIVE PROTEIN PHOSPHORYLATION BY PROTEIN KINASE C IN CELL ACTIVATION 787
59. PROTEIN KINASE ACTIVITIES OF NORMAL AND TRANSFORMED LYMPHOCYTES 803
60. DEFICIENCY OF 5'-DEOXY-5'-METHYLTHIOADENOSINE PHOSPHORYLASE IN HUMAN LEUKEMIA: BIOCHEMICAL ASPECTS AND CLINICAL IMPLICATIONS 817
61. THE ROLE OF MULTIPLE FORMS OF ALKALINE PHOSPHATASE IN CANCER DETECTION AND MONITORING 829
62. GLUTATHIONE TRANSFERASE AS A TUMOR MARKER IN HUMAN BREAST CARCINOMA 845
63. CANCER-RELATED CHANGES IN CREATINE KINASE ISOENZYMES AND VARIANTS 857
64. CLINICAL SIGNIFICANCE OF A REARRANGED HEXOKINASE ISOZYMES EXPRESSION IN NEOPLASTIC PHENOTYPE: THE ASTROCYTOMA MODEL 869
65. ANTIOXYGENIC ENZYMES AS TUMOR MARKERS: A CRITICAL REASSESSMENT OF THE RESPECTIVE ROLES OF SUPEROXIDE DISMUTASE AND GLUTATHIONE PEROXIDASE 883
66. NOVEL ASPECTS OF THE HUMAN ALDOLASE GENE FAMILY AND ITS EXPRESSION IN TUMOR CELLS 889
67. AUTHOR INDEX 899
68. SUBJECT INDEX 905
69. Backmatter 923